Agumadu Vivian C, Ramphul Kamleshun, Mejias Stephanie G, Sonaye Ruhi, Sombans Shaheen, Lohana Petras
Medicine, International University of the Health Sciences School of Medicine, Basseterre, KNA.
Pediatrics, Shanghai Jiao Tong University School of Medicine/Shanghai Xin Hua Hospital, Shanghai, CHN.
Cureus. 2018 Aug 27;10(8):e3216. doi: 10.7759/cureus.3216.
Asthma is a chronic respiratory condition that is characterized by reversible airflow obstruction. Interleukin-5 (IL-5) is involved in the pathophysiology of the disease and drugs targeting IL-5 have been studied for years as a possible treatment option for severe asthma. In this review, the authors searched PubMed for major drug therapies and clinical trials against IL-5. A total of 29 articles met the criteria for selection and were shortlisted; of these, 10 papers were on benralizumab, 14 on mepolizumab, and five on reslizumab. The three drugs proved to be safe and efficacious for patients with severe asthma, leading to decreased rates of asthma exacerbations, lowered levels of eosinophils, and improved pulmonary functions in various studies. Patients also reported an improvement in the quality of life. The side effects of these three drugs were mild and no deaths directly linked to the drug were reported. However, longer duration studies are required to draw firm and strong conclusions on the safety of these therapeutic agents.
哮喘是一种慢性呼吸道疾病，其特征为可逆性气流阻塞。白细胞介素-5（IL-5）参与了该疾病的病理生理过程，多年来，针对IL-5的药物一直作为重度哮喘的一种可能治疗选择进行研究。在本综述中，作者在PubMed上搜索了针对IL-5的主要药物疗法和临床试验。共有29篇文章符合入选标准并被列入候选名单；其中，10篇关于贝那利珠单抗，14篇关于美泊利单抗，5篇关于瑞利珠单抗。在各项研究中，这三种药物对重度哮喘患者均证明是安全有效的，可降低哮喘发作率、降低嗜酸性粒细胞水平并改善肺功能。患者还报告生活质量有所改善。这三种药物的副作用轻微，未报告与药物直接相关的死亡病例。然而，需要进行更长时间的研究才能对这些治疗药物的安全性得出确凿有力的结论。
